


2023-2024 Magellan Care Guidelines Summary of Revisions

EFFECTIVE NOV. 18, 2023

2023-2024 Magellan Care Guidelines Overview



Annual Review Cycle

Magellan Care Guidelines: effective Nov. 18, 2023

Naming convention: “2023-2024 Magellan Care Guidelines”



Changes include:

Upgrade to the *27th Edition* MCG Behavioral Health content

Updates to Magellan Healthcare Guidelines

2023-2024 Magellan Care Guidelines


- Magellan continues to use ASAM criteria for management of substance use services as required by state or customer contract.
- Magellan continues to use other State-mandated criteria, as required.
- CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) are used for Medicare, as required.
- Visit MagellanProvider.com/MNC for the latest information.

Summary of Changes: Magellan Healthcare Guidelines

2023-2024




2023-2024 Magellan Healthcare Guidelines



Four Magellan Healthcare Guidelines effective Nov. 18, 2023:

ORG/OTG	Magellan Healthcare Guidelines	Review
MHC-01-2023	Transcranial Magnetic Stimulation Treatment	Change to “Indications for Treatment”
MHC-40-2023	Outpatient Applied Behavior Analysis	Addition to Definitions, Appendix
MHC-03-2023	Psychological Testing	Change to “Exclusions”
MHC-31-2023	Neuropsychological Testing	Change to “Exclusions”

Update to Magellan Healthcare Guidelines



MHC-01-2023: Transcranial Magnetic Stimulation (TMS) Treatment: Commercial

Changes to “Indications for Treatment” I. C. 1) and 3):


I. Indications for Treatment

.....

C. One or more of the following:

- 1) The patient has demonstrated medication treatment resistance during the current depressive episode as evidenced by lack of a clinically significant response to at least ~~four (4)~~ **two(2)** failed trials of psychopharmacologic agents ~~including from~~ at least two (2) different agent classes. **The psychopharmacological agents are administered for the treatment of depression at both an adequate dose and adequate duration consistent with the FDA label and with a duration that would elicit a favorable response; or**
- 2) The patient has demonstrated an inability to tolerate psychopharmacologic agents as evidenced by two (2) trials of psychopharmacologic agents from at least two (2) different agent classes, with distinct side effects; *or*
- 3) The patient has a history of good response to TMS during an earlier episode of the treatment-resistant major depressive disorder as evidenced by a greater than 50% improvement in a standard rating scale for depressive symptoms. ~~The time between treatment episodes should allow for assessment clinically and by one of the rating scales to clearly document that the patient responded and then relapsed, is typically at least three (3) months since the last TMS session;~~ *or*

Update to Magellan Healthcare Guidelines




MHC-40-2023: Outpatient Applied Behavior Analysis

Addition of “Telehealth” to Definitions:

Telehealth: Telehealth is defined as the use of electronic information and telecommunication technologies to support long-distance clinical health care, patient and professional health-related education, health administration, and public health. Types of technologies that make up telehealth are: video conferencing, store-and-forward imaging, streaming media and land and wireless communications. Telehealth has expanded over the past decades. Telehealth experienced significant growth during and since the COVID-19 Public Health Emergency. Coordinating care has improved due to the advancement and role of technology. Research tends to support telehealth as an efficacious delivery method of behavioral health treatment interventions.

Update to Magellan Healthcare Guidelines




MHC-40-2023: Outpatient Applied Behavior Analysis

Addition of “Diagnosis of Autism Spectrum Disorder” to Appendix:

Diagnosis of Autism Spectrum Disorder:

There is an established and current (within 24 months) DSM-5-TR diagnosis of autism spectrum disorder using validated assessment tools. The diagnosis is confirmed by a doctoral-level clinician including a physician (family practice, pediatrics, developmental pediatrician, neurodevelopmental pediatrics, pediatric neurology, or psychiatry) or psychologist (PhD or PsyD). Examples of assessment tools are: Autism Diagnostic Observation Schedule (ADOS), Autism Diagnostic Interview (ADI-R), Parent Evaluation Developmental Stages (PEDS), Brigance Diagnostic Inventory of Early Development II; Modified Checklist for Autism in Toddlers (M-CHAT), Childhood Autism Rating Scale, Second Edition (CARS 2), Social Communication Questionnaire, Autism Spectrum Rating Scales (ASRS), Screening Tool for Autism in Toddlers and Young Children (STAT), Rapid Interactive Screening Test for Autism in toddlers (RITA-T), Social Communication Questionnaire (SCQ). The diagnosis includes examples and direct observations specific to the member consistent with DSM-5-TR criteria A and B for Autism Spectrum Disorder. *Note:* Checklist behaviors or general terms from DSM-5-TR are not acceptable without examples and direct observations specific to the member.

Update to Magellan Healthcare Guidelines



MHC-03-2023: Psychological Testing

MHC-31-2023: Neuropsychological Testing

Removal of a single exclusion criterion in both guidelines:


III. R. Exclusion Criteria: ~~The use of structured interview tools or interviews that do not have psychometric properties or normative comparisons is not a covered benefit.~~

Summary of Changes: MCG Guidelines®

27th edition



MCG Behavioral Health Care Guidelines



Changes to the 27th edition Behavioral Health Level of Care Guidelines

1) Gender Pronouns Updated to Improve Inclusivity:


“Gender pronouns have been updated where appropriate across content in the 27th edition to align with the *AMA Manual of Style* 11th edition changes, which permits use of "they" as a singular pronoun when rewriting the sentence as plural would be awkward or unclear. MCG updates the language and terminology used in our guidelines to be as specific and inclusive as possible, and we will continue to evaluate the content in this area.”

2) Addition of LOCUS/CALOCUS-CASII Level of Care Information to Clinical Indications for Admission:

“In the 27th edition of Behavioral Health Care, each level of care guideline (with the exception of Substance-Related Disorders) now includes the related LOCUS or CALOCUS-CASII level of care, the associated Composite Score, and a footnote that describes appropriate use of the Composite Score. This enhancement more easily allows users to confirm alignment of the specific MCG care guideline with external guidelines.”


MCG Health, 27th Edition Summary of Changes

MCG Care Guidelines *(will vary by health plan)*



MCG Guidelines® for 2023-2024
Inpatient Behavioral Health Level of Care, Adult
Inpatient Behavioral Health Level of Care, Child or Adolescent
Outpatient Behavioral Health Level of Care, Adult
Outpatient Behavioral Health Level of Care, Child or Adolescent
Residential Behavioral Health Level of Care, Adult
Residential Behavioral Health Level of Care, Child or Adolescent
Partial Hospital Behavioral Health Level of Care, Adult
Partial Hospital Behavioral Health Level of Care, Child or Adolescent
Intensive Outpatient Program Behavioral Health Level of Care, Adult
Intensive Outpatient Program Behavioral Health Level of Care, Child or Adolescent
Eating Disorders, Inpatient Behavioral Health Level of Care, Adult
Eating Disorders, Inpatient Behavioral Health Level of Care, Child or Adolescent
Eating Disorders, Residential Behavioral Health Level of Care, Adult
Eating Disorders, Residential Behavioral Health Level of Care, Child or Adolescent
Eating Disorders, Partial Hospital Behavioral Health Level of Care, Adult
Eating Disorders, Partial Hospital Behavioral Health Level of Care, Child or Adolescent
Eating Disorders, Intensive Outpatient Program Behavioral Health Level of Care, Adult
Eating Disorders, Intensive Outpatient Program Behavioral Health Level of Care, Child or Adolescent

MCG Care Guidelines *(will vary by health plan), cont'd*



MCG Guidelines® for 2023-2024

Substance-Related Disorders, Inpatient Behavioral Health Level of Care, Child or Adolescent

Substance-Related Disorders, Residential Behavioral Health Level of Care, Adult

Substance-Related Disorders, Residential Behavioral Health Level of Care, Child or Adolescent

Substance-Related Disorders, Partial Hospital Behavioral Health Level of Care, Adult

Substance-Related Disorders, Partial Hospital Behavioral Health Level of Care, Child or Adolescent

Substance-Related Disorders, Intensive Outpatient Program Behavioral Health Level of Care, Adult

Substance-Related Disorders, Intensive Outpatient Program Behavioral Health Level of Care, Child or Adolescent

Substance-Related Disorders, Outpatient Behavioral Health Level of Care, Adult

Substance-Related Disorders, Outpatient Behavioral Health Level of Care, Child or Adolescent


Medication-Assisted Opioid Withdrawal

Day Treatment Behavioral Health Level of Care

Observation Behavioral Health Level of Care, Adult

Electroconvulsive Therapy (ECT)

Education/Legal statement



The information contained in this presentation is intended for educational purposes only and is not intended to define a standard of care or exclusive course of treatment, nor be a substitute for treatment.

The information contained in this presentation is intended for educational purposes only and should not be considered legal advice. Recipients are encouraged to obtain legal guidance from their own legal advisors.